Skip to content

Clinical trials

Phase 2 Glioblastoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glioblastoma Phase: Phase 2 Clear all

582 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200010
200113
20029
200313
200411
200520
200623
200732
200827
200929
201025
201126
201218
201319
201420
201522
201622
201723
201817
201919
202024
202121
202217
202319
202428
202519
202623

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed295
Terminated85
Recruiting62
Unknown status47
Active, not recruiting46
Withdrawn26
Not yet recruiting17
Suspended3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)42
Duke University28
M.D. Anderson Cancer Center14
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins14
Dana-Farber Cancer Institute9
Memorial Sloan Kettering Cancer Center9
European Organisation for Research and Treatment of Cancer - EORTC8
Jonsson Comprehensive Cancer Center7
Mayo Clinic7
Northwestern University7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glioblastoma582
Brain Neoplasms184
Gliosarcoma176
Glioma156
Astrocytoma112
Central Nervous System Neoplasms90
Oligodendroglioma66
Recurrence26
Ependymoma20
Neoplasms12

Trials

Showing 26 to 50 of 582. Each trial links to its page on Pharma Observatory.

482 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.